Vaccination with immunogenic formulations of lymphomaderived immunoglobulin can elicit strong anti-idiotypic immune responses which have proved effective in murine B cell tumor challenge experiments and suggested possible benefits in recent human clinical trials. Naked plasmid DNA vaccines encoding the Id determinants as scFv fragments provide the most promising alternative to protein immunization. With this approach the addition of an immunogenic domain linked to the scFv has proved essential for the induction of a protective immune response. In this study we have produced a scFv gene construct linked to the CH3 exon of the human IgG1 constant region and tested its efficacy in inducing protective immunity against the mouse BCL1 lymphoma. We have also generated a second construct in which the BCL1 VL gene was deleted to investigate whether
Introduction
The variable regions of the immunoglobulin expressed by malignant B cells contain tumor specific idiotypic determinants that can be used as targets for active immunotherapy. These unique amino acid sequences are generated by genetic recombination and subsequent somatic hypermutation of variable (V) region genes and represent clonal signatures of the individual B cells. Although officially self antigens, these idiotypic determinants are potentially immunogenic to the host.
Induction of anti-idiotypic antibodies and protection against tumor challenge has been demonstrated in several mouse models using purified idiotypic protein as antigen for immunization. [1] [2] [3] [4] These studies have led to a few clinical trials of vaccination with idiotypic protein in patients with low grade lymphoma, which have produced encouraging results with significant antitumor immune responses and apparent clinical responses in a proportion of patients. 5, 6 However, the protein based approach is limited by the difficulty of producing sufficient quantities of idiotypic protein for each patient, the VH region domain contains sufficient antigenic determinants for a protective immune response. Both constructs induced anti-idiotypic antibodies that specifically reacted with the BCL1 IgM protein in ELISA and with BCL1 tumor cells in flow cytometry assays. Protection against tumor challenge was fully achieved with the complete scFv construct whereas immunization with the construct lacking the VL gene resulted in only a slight prolongation of the survival. We therefore conclude that a plasmid DNA vaccine containing the VH and VL genes of the lymphoma Ig linked to the human IgG1 CH3 exon is highly effective in inducing a protective immune response in the BCL1 model. We also demonstrated that VH gene immunization can induce strong antiidiotypic antibody responses. Gene Therapy (2000) 7, 605-611.
because current technology involving heterohybridomas or transfectomas is both expensive and time-consuming.
A more feasible approach for production of customized idiotypic vaccines relies on molecular cloning techniques and DNA-based antigen delivery systems. Plasmid DNA vaccination has been extensively tested in animal models and was found to be highly effective in inducing immune responses against a wide range of infectious agents and tumor antigens. 7 However, delivery of plasmids encoding tumor-derived variable regions in a single-chain Fv (scFv) conformation initially yielded disappointing results. A scFv construct that contained only the V genes of the murine BCL1 lymphoma induced low levels of anti-Id antibody and no protection from subsequent tumor challenge. 8 Protection improved by using a vector in which the tumor-derived V genes of the murine 38C13 B cell lymphoma were linked to sequences encoding a human constant region gene or an immunoenhancing peptide derived from IL-1␤. 9, 10 More recently, DNA vaccines in which the scFv construct was linked to a pathogen derived gene (fragment C of tetanus toxin) were shown to elicit protective immunity against the A31 murine B cell lymphoma, and also against a surface Ignegative murine myeloma. 11 These studies highlighted the necessity of adding an immuno-enhancing sequence to the scFv construct, but also raised questions regarding the mechanisms of anti-tumor immunity in these models.
With the aim of identifying the simplest vaccine formulation sufficient to induce an effective immune response we have produced a scFv gene construct containing the VH and VL genes from the BCL1 murine lymphoma linked to the CH3 exon of the human IgG1 constant region gene. Earlier studies showing that monoclonal Abs against the BCL1 idiotype act primarily with heavy chain determinants, 12 prompted us to investigate the efficacy of a second construct in which the BCL1 VL gene was deleted. Since for both protein and DNA immunizations the addition of the granulocyte-monocyte colony-stimulating factor (GM-CSF) has been shown to improve vaccine efficacy, [13] [14] [15] [16] we co-administered a GM-CSF encoding vector with each of the antigen-containing plasmids.
Results

Analysis of the antibody response
The constructs used for the genetic immunizations are depicted in Figure 1a . Both constructs were transfected into an eukaryotic cell line to assess the expression and secretion of the encoded proteins. As shown in Figure 1b the complete scFv-CH3 protein was present both in the intracellular and the extracellular compartments, indicating that the protein is efficiently secreted. On the contrary, the VL deletion protein was detected only in the cell lysate.
The ability of each construct to induce an antibody response against the idiotype and against the human CH3 portion was analyzed on sera collected 2 weeks after the last boost. As shown in Figure 1c immunization with both constructs, pBCL1 and p⌬VL, co-administered with pGM-CSF induced detectable levels of anti-Id antibodies in 100% of cases. However, the mean value in case of the construct containing both VH and VL determinants was higher (mean E 492 pBCL1 = 1.63, mean E 492 p⌬VL = 1.0, P = 0.027). Immunization with the pBCL1 plasmid without the adjuvant pGM-CSF plasmid only slightly affected the anti-Id antibody levels (mean E 492 = 1.45). The same tendency was observed when analyzing the response against the exogenous human CH3 portion, with higher mean values in the pBCL1 immunized groups (mean E 492 = 1.84 and mean E 492 = 1.6 for pBCL1 with and without pGM-CSF, respectively), and lower values for p⌬VL group (mean E 492 = 1.4). A control group immunized with pGM-CSF alone failed to induce detectable levels of either anti-Id or anti-CH3 antibodies. In most mice the anti-Id antibody levels correlated with the anti-CH3 response. Interestingly, the IgG subclass profile of the anti-Id antibodies indicated that in the presence of pGM-CSF, the pBCL1 plasmid induced comparable levels of IgG1 and IgG2a subclass Abs, whereas the response induced by pBCL1 alone was dominated by IgG1 Abs (Figure 2 ). In contrast, the response to p⌬VL vaccination was dominated by IgG2a Abs, which is considered a predominantly Th1 type of response. This difference in IgG subclass profile may reflect the difference in the amount of protein secreted by the in vivo transfected cells.
Reactivity with tumor cells
The anti-Id antibodies induced by the two constructs were tested for their ability to bind the native antigen expressed on the surface of the BCL1 lymphoma cells. Figure 3 shows strong binding of tumor cells by pBCL1-induced Abs and a reduced but still significant binding for Abs induced by p⌬VL. This is in agreement with the lower number of epitopes available on the cell surface to be bound by sera raised only against VH determinants when compared with sera raised against both VH and VL determinants. Binding to WEHI-231, a murine B cell lymphoma expressing an unrelated surface IgM was not significant (data not shown).
Tumor growth and survival after tumor challenge Twenty days after the last immunization mice were challenged with 10 6 BCL1 lymphoma cells. The kinetics of tumor growth were followed by an Ig gene fingerprinting assay, which allowed precise evaluation of the degree of expansion of the malignant clone relative to the amount of the residual normal B cell in the peripheral blood of the challenged animals. The assay was performed on RNA extracted from PBMC on day 50 after tumor challenge. As shown in Figure 4 , the pattern of a normal mouse is polyclonal with a ladder of bands representing CDR3 of different lengths. Control animals challenged with BCL1 tumor cells showed a unique band corresponding to the length of the BCL1-specific CDR3, indicating that the malignant clone had overgrown the normal B cells. The group of mice immunized with the pBCL1 construct showed a pattern that was identical to the one of the unchallenged animal, indicating rejection or much slower progression of the tumor. For the p⌬VL group, 50% of the animals showed a polyclonal pattern while in the remaining 50% the monoclonal population of BCL1 cells was clearly detectable, but residual normal B cells were also present.
Prediction made on the basis of the fingerprinting analysis correlated strictly with the survival time. As shown in Figure 5 , unvaccinated animals as well as animals in the control pGM-CSF vaccinated group died by day 100 with a mean survival of 86 and 90 days, respectively. All animals immunized with the plasmid containing the complete scFv construct in combination with the pGM-CSF plasmid mounted protective immune responses and were still alive after 220 days of follow-up (P Ͻ 0.001). Mice immunized with the p⌬VL construct survived significantly longer than animals in the control groups (mean 118 days, P Ͻ 0.05) but all of them still died by day 150. As expected, mice showing a polyclonal pattern at the time of fingerprinting analysis died later than those showing a monoclonal pattern. The effect of the adjuvant plasmid pGM-CSF in terms of protection consisted in augmented percentage of protected animals. In fact, immunization with pBCL1 alone led to survival of more than 220 days in 70% of the cases, while the other animals died in the same period as control animals. Although mean anti-Id antibody levels correlated well with mean survival of the different groups, analysis of individual sera within the p⌬VL group revealed a lack of correlation between longer survival and better Ab response in terms of ELISA values. This lack of correlation has been previously noted for both protein and DNA vaccination.
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Discussion
Our study focuses on the need to further improve the efficacy and to facilitate the production of DNA vaccines for active immunotherapy of B cell malignancies. The model that we chose, the mouse BCL1 lymphoma, has been extensively studied in this context. 4, 8, [17] [18] [19] Earlier studies had shown that the BCL1 Ig coupled to KLH can induce an anti-idiotypic immune response that suppresses tumor development. 4, 19 However, immunization with a plasmid DNA construct encoding only the VH and VL regions of the BCL Ig failed to evoke a protective immune response. 8 Therefore, our first goal was to augment the immunogenicity of the idiotype V regions. A few recent studies with two other B cell lymphoma models showed improved survival in mice immunized with DNA vaccines in which the VH and VL genes in a scFv format were linked to a human Ig constant region, an IL-1␤ peptide or fragment C of tetanus toxin. [9] [10] [11] We decided to test the efficacy of the CH3 domain of human IgG1 in this context, since previous work in our laboratory had Gene Therapy shown that scFv-␥CH3 molecules are optimally folded and efficiently assembled and secreted by transfected mammalian cells. 20 We also reasoned that the use of a xenogenic Ig domain may have advantages in terms of prospective clinical trials, considering that in humans a parallel approach would be to use constant region domains of mouse Ig. Mouse monoclonal antibodies have been extensively used in humans and have shown no serious side-effects or toxicities.
The data presented in this study show that our approach is highly effective in inducing protective antitumor immunity. Seventy percent of the animals immunized with the BCL1 scFv-␥CH3 plasmid (pBCL1) and 100% of the animals co-immunized with pBCL1 and pGM-CSF were still alive at the end of the study. However, it must be noted that 130 days after tumor chal- lenge, BCL1 B cells could be detected in all animals using sensitive PCR analysis of Ig gene rearrangements, indicating that the immune response induced a state of tumor dormancy rather than complete rejection of the malignant B cells.
Anti-Id Abs induced by vaccination with the BCL1 IgM protein have been shown to react primarily with antigenic determinants in the VH region. 12 This observation prompted us to investigate the possibility of using VH gene immunization for active immunotherapy of lymphoma. Two previous reports had shown that anti-V region antibodies can be raised in mice by immunizing with human VK and VH gene constructs. 21, 22 Our study extends on these observations, showing that anti-Id antibodies can be induced with this approach also against autologous V regions. Immunization with a gene construct in which the VL gene of the BCL1 scFv was deleted, elicited detectable levels of anti-Id Abs in most animals. Most importantly, these antibodies were able to bind the native antigen expressed on BCL1 tumor cells, ie they can recognise properly folded idiotypic determinants. Induction of antibodies against an intracellular antigen was reported in other systems. 23, 24 The effect of the compartment in which the plasmid encoded antigen is expressed was shown to reside in a deviation of the serum immunoglobulin isotype profile. 24 We have indeed observed the same pattern of deviation with a predominance of IgG1 subclass for the secreted protein and of IgG2a for the intracellular one. However, although the survival of animals immunized with this plasmid was significantly longer than that of control animals (P Ͻ 0.05), no long-term survivors were observed. Apparently, the immune response induced in the p⌬VL group resulted in only slower progression of the tumor, which was also noted by comparing the clonality of the Ig gene rearragements at early stages after tumor challenge.
Concerning the mechanism that induces protection, we failed to detect cytotoxic T cells able to lyse BCL1 tumor cells (data not shown). Similar results have been reported by other groups, 11, 25 suggesting that the protective effect of DNA vaccination in the case of B cell lymphoma is largely dependent on idiotype-specific humoral immunity. In this setting it is interesting to stress again that true protection was not observed in any of the VH gene immunized animals, although in some of them the titers of anti-Id Abs were higher than in mice immunized with the complete scFv DNA vaccine. Although it is difficult to provide a documented explanation for this discrepancy, one possibility could be the higher number of antigenic determinants on the surface of the malignant B cells available to react with the wider antibody repertoire induced by the VH/VL vaccine. Alternatively, the type of T helper cell response may be responsible for the difference in outcome. Based on IgG subclass analysis of the anti-idiotypic antibodies, it appears that the p⌬VL plasmid induced a predominantly Th1 type response, whereas a Th2 type response was seen in the pBCL1 immunized animals.
In conclusion, our results indicate that for DNA-based immunotherapy of lymphoma both the VH and the VL gene are required for clinically relevant anti-tumor response. This may not necessarily be true for other B cell malignancies, such as multiple myeloma, where protection induced by scFv DNA vaccination apparently does not rely on the presence of anti-Id Abs, but rather on the induction of CD4 + T cells reactive with the tumor. 11 Considering that the absence of certain conformational Id determinants in the VH gene vaccine would not be relevant for this type of immune response, it may be interesting to investigate whether the VH gene DNA vaccine can be useful in this setting. 
Materials and methods
Mice and cell lines
Ten to 12-week-old Balb/c mice were obtained from Harlan (Milan, Italy) and housed at the ICGEB animal house. BCL1 is a spontaneous B cell leukemia/lymphoma of BALB/c origin that expresses high levels of surface IgM/l. 26 The cell line exists in two variants which express the same surface IgM idiotype. The original BCL1 clone was used in the tumor challenge experiments and was maintained through serial passages in syngeneic BALB/c mice. BCL1 3B3 is a variant that unlike the original clone can be maintained in tissue culture and was used for FACS analysis and RNA extraction. Plasmids and DNA preparation Total RNA was isolated from BCL1 3B3 cells using the guanidinium thiocyanate procedure and reverse transcribed using random hexamers and the GeneAmp RNA/PCR kit (Perkin Elmer Cetus, Norwalk, CT, USA). The tumor-derived VH region was amplified from the cDNA using the sense primer VH/PstI (5Ј-GTG CAGCTGCAGCAGTCTGG) and the antisense primer mjH/BspEI (5Ј-AGAGCCTCCGGAGGAGACTGTGA GAGT). The VL region was amplified using the sense primer VL/ApaLI (5Ј-TAGTGCACTCGCAGGCTGTTG TGACTCA) and the antisense primer JL/SpeI (5Ј-GCACTAGTGCTGCCACCTAGGACAGTGACCTT). The PstI/BspEI VH fragment and the ApaLI/SpeI VL fragment were then cloned into the pUT-SEC plasmid containing a HindIII/ApaLI genomic secretion signal sequence. 20 In the final step the HindIII/BspEI fragment (signal peptide-VL-linker-VH) was subcloned in a pcDNA3 vector containing a human IgG1 CH3 domain cloned as a HindIII/KpnI fragment resulting in plasmid pBCL1. Deletion of the VL gene segment by removing the SpeI fragment (VL contains an internal SpeI site at position 102) generated plasmid p⌬VL (Figure 1a) . For the construction of pGM-CSF total RNA was extracted from mouse splenocytes and subjected to an RT-PCR step using the forward primer HindIII-GM (5Ј-CTAAGC TCCTGAGGAGGATGTGGC) and the reverse primer Xho-GM (5Ј-CCCTCGAGTCCTCATTTTTGGACTGGTT). The amplified fragment was then inserted in the polylinker of pcDNA3 as a HindIII/XhoI fragment. Plasmid vectors were purified using the Qiagen Plasmid Mega kit (Qiagen, Hilden, Germany) and resuspended in saline. The ratio of OD 260/280 ranged from 1.8 to 2.0. Endotoxin assays were performed using E-Toxate (Sigma Chemical, St Louis, MO, USA) and were below 1 endotoxin U/g of DNA.
Immunization protocol followed by tumor challenge Balb/c mice were vaccinated four times at 2-week intervals by intradermal injection of 100 g plasmid DNA vaccine (pBCL1 or p⌬VL) plus 100 g of pGM-CSF or 100 g of pcDNA3. Control animals were mock vaccinated with 100 g pcDNA3 plus 100 g of pGM-CSF. Two weeks after the last boost, immune sera were collected via retro-orbital puncture. Twenty days after the last boost mice were challenged with 10 6 viable BCL1 tumor cells injected i.p.
Transfection, in vivo labeling, immunoprecipitation Sp2/0 cells were transfected by electroporation as described elsewhere 27 and selected with 400 g/ml of G418 (Geneticin, Life Technologies, Gaithersburg, MD, USA). In vitro labeling was performed by incubating 2 × 10 6 cells in the presence of 35 S methionine at 100 Ci/ml. After 4 h of incubation supernatants and cellular extracts were immunoprecipitated with anti-human IgG antibodies (Sigma) and purified by protein A-sepharose. The samples were analyzed by SDS/PAGE in the presence of ␤-mercaptoethanol.
Measurement of Ab response
The immune response of vaccinated mice was measured by ELISA. To determine the levels of anti-idiotypic Abs, immune sera were diluted on plates coated with 3 g/ml of BCL1 IgM previously immunopurified from the 123bcl1 hybridoma supernatant. Reactivity against the human CH3 portion was determined using plates coated with 3 g/ml human IgG (Sigma). Bound murine Abs were detected with (HRPO)-conjugated goat anti mouse IgG (Kirkegaard and Perry, Gaithersburg, MD, USA). For the analysis of IgG subclasses sera were diluted on plates coated with 3 g/ml of BCL1 IgM and bound antibodies were detected by incubating plates with unlabeled sheep anti mouse IgG1 or IgG2a (Serotec, Oxford, UK) followed by (HRPO)-conjugated anti sheep antibodies (Dako, Glostrup, Denmark).
FACS analysis
Sera from immunized mice collected 2 weeks after the last boost were analyzed for their ability to bind surface IgM on 3B3 BCL1 cells. The cells were incubated at 4°C with 200 l of Id reactive sera (diluted 1:40 in 3% BSA/PBS containing 0.02% NaN3) Bound Abs were detected with goat anti-mouse IgG (Kirkegaard and Perry) and FITC conjugated rabbit anti-goat Abs (Dako). Fluorescence analysis was performed with a FACS Calibur (Becton Dickinson, Mountain View, CA, USA).
Ig gene fingerprinting analysis
The presence of the BCL1 clone in PBMC of challenged animals was investigated using an Ig gene fingerprinting procedure. Total cellular RNA was isolated from blood samples collected 50 days after tumor challenge. After reverse transcription cDNA was PCR amplified using a consensus mouse FW1 specific primer (mFW1: 5Ј GTGCAGCTGCAGCAGTCTGG 3Ј) and a primer specific for the Cm region (mM1: 5Ј GGGAAGACATTTGGGAA GGA 3Ј). The PCR amplified fragments were labeled by primer extension with two internal 32 P-end-labeled oligonucleotides: mFW3, complementary to a conserved region in the mouse FW3 region (5Ј (CT)TG ACATCTGA(GC)GA(CT)TCT 3), and BCL1sp, complementary to a sequence in the CDR3 of the BCL1 VH (5Ј AGATACTATGGTAACTACT 3Ј) located 18 nts downstream from the mFW3 oligonucleotide. The reaction mixtures (20 l of the PCR samples, 10 pm of 32 P-endlabeled oligonucleotide 200 l dNTP, 2.5 l of Gene Amp 10 × PCR buffer and 1.25 U of Taq polymerase in a final volume of 25 l) were subjected to denaturation at 95°C for 8 min, annealing at 52°C for 1 min and extension at 72°C for 15 min. Two l of each reaction were analyzed on denaturing 6M urea 6% polyacrylamide sequencing gels with sequencing reactions used as size markers.
Statistical analysis
Comparison of means was done with the Student's test. Survival analysis were performed using the KaplanMeier product-limit method and the log-rank test.
